

BETH C. DRAIN, CA CSR NO. 7152

BEFORE THE
SCIENCE SUBCOMMITTEE OF THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: VIA ZOOM

DATE: VIA ZOOM
3:30 P.M.

REPORTER: BETH C. DRAIN, CA CSR NO. 7152

FILE NO.: 2025-23

**133 HENNA COURT, SANDPOINT, IDAHO 83864
208-920-3543 CACSR7152@OUTLOOK.COM**

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

I N D E X

ITEM DESCRIPTION	PAGE NO.
OPEN SESSION	
1. CALL TO ORDER	3
2. ROLL CALL	3
3. CONSIDERATION OF THE EDUC8 CONCEPT PLAN	4
4. CONSIDERATION OF THE EDUC3 (SPARK) CONCEPT PLAN AMENDMENT	28
5. UPDATE REGARDING THE CIRM	38
6. PUBLIC COMMENT	51
7. ADJOURNMENT	53

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

NOVEMBER 21, 2025; 3:30 P.M.

CHAIRMAN FISCHER-COLBRIE: WHY DON'T WE GO AHEAD AND GET STARTED. SO I'D LIKE TO CALL TO ORDER THE SCIENCE SUBCOMMITTEE MEETING. AND WITH THAT, IF WE CAN START THE ROLL CALL, SCOTT, THAT WOULD BE GREAT.

MR. TOCHER: OKAY. MARIA BONNEVILLE.

VICE CHAIR BONNEVILLE: PRESENT.

MR. TOCHER: DEBORAH DEAS. MARK FISCHER-COLBRIE.

CHAIRMAN FISCHER-COLBRIE: HERE.

MR. TOCHER: ELENA FLOWERS.

DR. FLOWERS: PRESENT.

MR. TOCHER: JUDY GASSON. VITO IMBASCIANI.

CHAIRMAN IMBASCIANI: HERE.

MR. TOCHER: PAT LEVITT.

DR. LEVITT: HERE.

MR. TOCHER: SHLOMO MELMED.

DR. MELMED: HERE.

MR. TOCHER: CAROLYN MELTZER.

DR. MELTZER: PRESENT.

MR. TOCHER: CHRIS MIASKOWSKI.

DR. MIASKOWSKI: PRESENT.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. TOCHER: SHAUNA STARK. KAROL WATSON.
2 KEITH YAMAMOTO.

3 DR. YAMAMOTO: HERE.

4 MR. TOCHER: GREAT. THANKS VERY MUCH.
5 MARK, WE HAVE A QUORUM.

6 CHAIRMAN FISCHER-COLBRIE: GREAT. THANKS,
7 SCOTT. WITH THAT, I'D LIKE TO TURN IT OVER TO DAISY
8 FOR A QUICK INTRODUCTION AND FOR CONSIDERATION OF
9 THE EDUC8 CONCEPT PLAN. AND THE DISCUSSION WILL
10 TODAY COVER BOTH THE EDUC8 AND THE EDUC 3 PROGRAMS.
11 WITH THAT, I'M GOING TO TURN THAT OVER TO DAISY'S
12 CAPABLE HANDS.

13 MS. XIN: GREAT. THANKS, MARK. HI,
14 EVERYONE. MY NAME IS DAISY, AND I'M ONE OF THE
15 SCIENCE OFFICERS WITH THE DISCOVERY AND EDUCATION
16 TEAM. SO LET ME JUST SHARE MY DECK. ALL RIGHT.

17 SO I WILL BE SHARING WITH YOU TODAY ON THE
18 EDUC8 AND EDUC3 CONCEPTS. ALL RIGHT. NOW, FIRST,
19 JUST A BRIEF REMINDER THAT THE SAF GOAL 6
20 RECOMMENDATION IS TO BOLSTER CIRM'S -- GOAL 6 IS TO
21 BOLSTER CIRM'S WORKFORCE DEVELOPMENT PROGRAMS TO
22 ADDRESS GAPS AND MEET EVOLVING DEMANDS IN
23 REGENERATIVE MEDICINE. AND TO DO THAT, WE'LL BE
24 PROVIDING HIGH-DEMAND TECHNICAL TRAINING VIA THE
25 BRIDGES AND COMPASS PROGRAM UPDATES AS WELL AS

BETH C. DRAIN, CA CSR NO. 7152

1 DEVELOP PROGRAMMING TO SUPPORT OUTREACH EDUCATION
2 EFFORTS FOR K THROUGH 12 STUDENTS, TEACHERS, AND
3 COMMUNITY MEMBERS VIA COLLABORATIONS.

4 SO I'LL FIRST GO OVER THE EDUC8 CONCEPT.
5 AND WHAT YOU CAN EXPECT FROM THIS PRESENTATION IS A
6 QUICK BACKGROUND, INCLUDING THE OVERVIEW OF OUR
7 MISSION AND EDUC PROGRAMS. I'LL BE FOCUSING IN ON
8 BRIDGES AND COMPASS SPECIFICALLY AND GIVING YOU THE
9 RATIONALE THAT WE HAVE FOR EDUC8. THE REST OF THE
10 PRESENTATION WILL BE ON MORE DETAILS ON THE EDUC8
11 CONCEPT FOLLOWED BY A TIMELINE OF ROLLING OUT THE
12 PROGRAM AND A QUICK SUMMARY AND REQUEST FOR A
13 MOTION.

14 SO AS YOU ALL KNOW, CIRM'S MISSION IS
15 ACCELERATING WORLD-CLASS SCIENCE TO DELIVER
16 TRANSFORMATIVE REGENERATIVE MEDICINE TREATMENTS IN
17 AN EQUITABLE MANNER TO A DIVERSE CALIFORNIA AND
18 WORLD.

19 AND REALLY KEY TO THIS MISSION IS
20 EDUCATION AND WORKFORCE DEVELOPMENT AND TRAINING AND
21 IS REALLY A FOUNDATION ON THIS PYRAMID THAT
22 REPRESENTS CIRM'S INVESTMENT IN TRAINING PROGRAMS
23 ACROSS CALIFORNIA. THAT'S PREPARING THE NEXT
24 GENERATION OF SCIENTISTS, TECHNICIANS, CLINICIANS
25 WHO WILL BE THE ONES DRIVING THE REGENERATIVE

BETH C. DRAIN, CA CSR NO. 7152

1 MEDICINE ECOSYSTEM.

2 NOW, ON TOP OF THIS FOUNDATION ARE
3 INFRASTRUCTURE PROGRAMS THAT WILL ENHANCE DISCOVERY
4 AS WELL AS RESEARCH AND DEVELOPMENT THROUGH OUR
5 DISC, PDEV, AND CLIN2 PILLARS WHERE THOSE INNOVATIVE
6 DISCOVERIES ACTUALLY TRANSLATE INTO NEW THERAPIES
7 AND TREATMENTS FOR PATIENTS.

8 NOW, THIS PYRAMID IS SUPPORTED BY THE
9 EDUCATION AND WORKFORCE DEVELOPMENT PROGRAMS THAT
10 ARE TRAINING PROFESSIONALS WHO ARE THE ONES
11 DESIGNING THE EXPERIMENTS, MANAGING THE DATA, AND
12 PRODUCING THERAPIES, AND THE CARE FOR PATIENTS. AND
13 THIS IS WHERE CIRM'S EDUC PROGRAMS REALLY PLAY A KEY
14 ROLE IN GUIDING TRAINEES TO APPLY AND ADAPT THESE
15 LEARNED SKILLS TO TACKLE FUTURE CHALLENGES, TO
16 CONTRIBUTE VALUABLE RESEARCH AND INSIGHTS THAT DRIVE
17 SCIENTIFIC INNOVATION, AS WELL AS CONTRIBUTE VERY
18 VALUABLE PERSPECTIVES THAT ARE REFLECTING THE
19 BREADTH OF THE CALIFORNIA COMMUNITIES THAT THEY COME
20 FROM.

21 IN MANY WAYS THEY'RE ALSO GIVING BACK TO
22 THEIR COMMUNITIES WITH THEIR KNOWLEDGE. AND IN
23 PARTICULAR, OUR PROGRAMS ALSO EMPHASIZE PATIENT
24 ENGAGEMENT AND COMMUNITY OUTREACH SKILLS. AND ALL
25 OF THAT TOGETHER REALLY PROVIDE A HOLISTIC TRAINING

BETH C. DRAIN, CA CSR NO. 7152

1 THAT DRIVE THAT HOME.

2 SO ONE QUOTE THAT I REALLY LIKE FROM ONE
3 OF OUR RECENT BLOG POSTS ON OUR BLOG, THE *STEM*
4 *CELLAR*, I THINK REALLY SPEAK TO THIS MESSAGE. AND
5 THAT'S THAT EDUCATION PROGRAMS BUILD THE
6 BIOTECHNOLOGY WORKFORCE THAT'S NEEDED TO GENERATE
7 NEW CURES.

8 NOW, CIRM'S CURRENT PORTFOLIO OF TRAINING
9 PROGRAMS SPAN A RANGE OF TRAINING LEVELS FOR
10 STUDENTS STARTING FROM HIGH SCHOOL STUDENTS ALL THE
11 WAY TO GRADUATE, POST-DOC, FELLOWS AND CLINICAL
12 FELLOWS. AT THE BOTTOM HERE WE FIRST HAVE SPARK
13 WHICH IS OUR PROGRAM THAT PROVIDES SUMMER INTERNSHIP
14 OPPORTUNITIES FOR HIGH SCHOOL STUDENTS. WE
15 CURRENTLY HAVE 11 ACTIVE PROGRAMS THROUGHOUT THE
16 STATE. AND SINCE 2012 WE'VE TRAINED OVER 950
17 STUDENTS.

18 NEXT WE HAVE OUR COMPASS PROGRAM, WHICH IS
19 OUR NEWEST PROGRAM, ACTIVE SINCE 2023. AND WE'VE SO
20 FAR TRAINED OVER 300 STUDENTS. THERE'S 54 PERCENT
21 OF COMPASS STUDENTS WHO ARE FIRST-GENERATION COLLEGE
22 STUDENTS. AND THIS IS A PROGRAM THAT IS TARGETED AT
23 TRAINEES WHO ARE PURSUING A BACHELOR'S DEGREE. AND
24 TYPICALLY THESE ARE TRAINEES WHO ARE EARLIER STAGE
25 WHO MAYBE ARE CURIOUS ABOUT BIOLOGY, BUT NOT QUITE

BETH C. DRAIN, CA CSR NO. 7152

1 SURE OF ALL THE DIFFERENT TYPES OF OPPORTUNITIES
2 THAT ARE AVAILABLE IN THE STEM CELL FIELD. SO THIS
3 PROGRAM IS REALLY GUIDING THOSE STUDENTS TO EXPLORE
4 DIFFERENT TYPES OF OPPORTUNITIES AND CAREERS IN THE
5 FIELD.

6 WE ALSO HAVE OUR BRIDGES PROGRAM, WHICH IS
7 OUR LONGEST RUNNING PROGRAM SINCE 2009. WE'VE
8 TRAINED OVER 2,000 STUDENTS, AND 47 PERCENT OF
9 BRIDGES STUDENTS ARE FIRST-GENERATION COLLEGE
10 STUDENTS. WE HAVE 15 ACTIVE PROGRAMS RIGHT NOW
11 SPREAD OUT IN DIFFERENT CAL STATE UNIVERSITIES AND
12 COMMUNITY COLLEGES THROUGHOUT CALIFORNIA. AND THE
13 BRIDGES PROGRAM IS OFFERING A LONG ONE-YEAR
14 INTERNSHIP, SIX- TO 12-MONTH INTERNSHIP REALLY, FOR
15 STUDENTS WHO ARE MORE COMMITTED TO THE STEM CELL AND
16 BIOLOGY FIELDS. AND THOSE ARE STUDENTS THAT
17 TYPICALLY ARE READY TO JUMPSTART THEIR CAREERS UPON
18 COMPLETION OF THE PROGRAM. AND THIS PROGRAM IS
19 TYPICALLY INTEGRATED INTO ASSOCIATE DEGREES,
20 BACHELOR'S, AND MASTER'S DEGREE PROGRAMS AT
21 INSTITUTIONS.

22 AND LAST BUT NOT LEAST, WE HAVE OUR EDUC4
23 PROGRAM ALSO KNOWN AS SCHOLARS. THERE ARE 18 ACTIVE
24 PROGRAMS ACROSS CALIFORNIA, AND WE'VE TRAINED 1300
25 STUDENTS, OVER 1300 STUDENTS SINCE 2007. AND THIS

BETH C. DRAIN, CA CSR NO. 7152

1 PROGRAM SUPPORTS GRADUATE STUDENTS, POSTDOCTORAL
2 FELLOWS, AND CLINICAL FELLOWS.

3 AND THE GOAL OF ALL OF OUR PROGRAMS REALLY
4 IS TO BUILD A SKILLED WORKFORCE CAPABLE OF MEETING
5 THE EVOLVING DEMANDS IN REGENERATIVE MEDICINE. BUT
6 TODAY I'LL BE FOCUSING ON THE BRIDGES AND COMPASS
7 PROGRAMS IN PARTICULAR. AS I MENTIONED, BOTH
8 PROGRAMS TRAIN UNDERGRADUATE AND BRIDGES TRAINEES,
9 MASTER'S STUDENTS AS WELL. THE CURRENT AWARDS WE
10 HAVE SPAN CALIFORNIA, AND THERE ARE ACTUALLY SIX
11 INSTITUTIONS THAT HAVE BOTH BRIDGES AND COMPASS
12 PROGRAMS, AND I'LL COME BACK TO THAT LATER.

13 THE MAJORITY OF TRAINEES THAT WE SEE THAT
14 GO THROUGH OUR BRIDGES AND COMPASS PROGRAMS REMAIN
15 IN STEM FIELDS. SO A NOTE HERE THAT THESE ARE
16 SPECIFIC ALUMNI OUTCOMES SPECIFIC TO THE BRIDGES
17 PROGRAM. SINCE COMPASS IS STILL QUITE NEW, WE DON'T
18 HAVE A LOT OF ALUMNI INFORMATION JUST YET. BUT AS
19 BRIDGES HAS BEEN RUNNING SINCE 2009, WE HAVE QUITE A
20 BIT OF ALUMNI OUTCOME DATA. AND WE SEE THAT 83
21 PERCENT OF STUDENTS ACTUALLY REMAIN IN STEM FIELDS.
22 ABOUT 37 PERCENT OF THEM GO ON TO DO ACADEMIC
23 RESEARCH OF SOME KIND. 31 PERCENT GO INTO THE
24 BIOTECH INDUSTRY, AND ABOUT 24 PERCENT CONTINUE TO
25 PURSUE HIGHER EDUCATION.

BETH C. DRAIN, CA CSR NO. 7152

1 NOW, WITH BOTH BRIDGES AND COMPASS, OUR
2 TRAINEES ALSO HELP GROW AND PARTICIPATE IN THE
3 WORKFORCE DEVELOPMENT NETWORK OVERALL. AND THROUGH
4 THESE PROGRAMS WE'VE SEEN OVER 90 INTERNSHIP HOST
5 SITES AND LABS THAT SUPPORT AND GUIDE OUR STUDENTS,
6 49 OF WHICH ARE BIOTECH INDUSTRY HOSTS. AND
7 ALTOGETHER SO FAR WE HAVE HAD OVER 800 MENTORS
8 HELPING MENTOR AND GUIDE THESE STUDENTS THROUGH
9 THESE PROGRAMS.

10 NOW, TRAINEES ARE ALSO MAKING AN IMPACT
11 ALONG THE ENTIRE PIPELINE FROM DISCOVERY ALL THE WAY
12 TO CLINICAL AND ACTUALLY INNERVATING AND EXPANDING
13 THE FIELD IN MANY WAYS. WITH BOTH BRIDGES AND
14 COMPASS, WE HAVE A LOT OF GREAT ANECDOTES. SO WE'VE
15 HEARD FROM MENTORS OVER THE YEARS. THIS ONE IN
16 PARTICULAR IS FROM KATHY IVEY WHO IS A VP AT TENAYA
17 AND ACTUALLY HERSELF IS A CIRM SCHOLAR ALUM. SO
18 THAT'S REALLY COOL. BUT SHE SHARED WITH US THAT A
19 TRAINEE HELPED SEED THEIR HISTOLOGY CORE AND GET IT
20 OFF THE GROUND.

21 WE'VE ALSO HEARD FROM OTHER PI'S. THIS IS
22 FROM IT KAREN ABOODY, WHO IS A PI AT CITY OF HOPE,
23 SHARED WITH US THAT TRAININGS HAVE IMPACTED THE
24 DESIGN OF THEIR CLINICAL PROTOCOL AND PROGRESS FOR
25 IND SUBMISSION.

BETH C. DRAIN, CA CSR NO. 7152

1 NOW, OVERALL WITH THESE PROGRAMS, WE'VE
2 SEEN OVER 500 PUBLICATIONS IN PEER REVIEW JOURNALS
3 THAT WERE ENABLED THROUGH THIS TRAINING. THIS IS
4 REPORTED TO US BY PROGRAM DIRECTORS IN THEIR ANNUAL
5 REPORT TO CIRM.

6 NOW, THE IMPACT OF THESE PROGRAMS ARE
7 REALLY GREAT AND CONTINUING THEM IS ESSENTIAL. AS
8 MANY OF YOU MAY KNOW, THE CURRENT BRIDGES PROGRAM IS
9 EXPIRING IN THE FALL OF 2026, AND COMPASS WILL BE
10 EXPIRING A YEAR AFTER THAT. AND SUSTAINING THESE
11 PROGRAMS REALLY IS CRUCIAL TO ACHIEVING CIRM'S
12 MISSION. AT THIS TIME OF FUNDING INSTABILITY
13 ESPECIALLY, SUPPORT IS VERY CRITICAL.

14 SO WE ARE PROPOSING TO RELAUNCH THESE
15 PROGRAMS WITH SOME UPDATES BASED ON THE EXPERIENCE
16 WE'VE HAD MANAGING THESE PROGRAMS.

17 WE WANT TO PRESERVE PROGRAM CONTINUITY IN
18 ORDER TO TAKE ADVANTAGE OF EXISTING INFRASTRUCTURES
19 THAT ARE ALREADY IN PLACE, TO BE ABLE TO RESPOND TO
20 FUNDING CHALLENGES AS WELL, AND TAKE THE OPPORTUNITY
21 TO IMPLEMENT SOME IMPROVEMENTS BASED ON THE FEEDBACK
22 WE'VE GOTTEN OVER THE PAST 15 YEARS.

23 SOME KEY INSIGHTS THAT WE'VE GOTTEN FROM
24 ACTIVE BRIDGES AND COMPASS PROGRAMS SO FAR IS THAT
25 THERE ARE EVER EVOLVING DEMANDS OF THE FIELD,

BETH C. DRAIN, CA CSR NO. 7152

1 ESPECIALLY IN THE CURRENT FUNDING CLIMATE. AND SO
2 WE'LL BE OFFERING AN EXPANDED ARRAY OF INTERNSHIP
3 OPPORTUNITIES AS WELL AS ENCOURAGING DEVELOPMENT OF
4 HYBRID AND MULTIDISCIPLINARY SKILLSETS FOR STUDENTS.

5 AS I MENTIONED BRIEFLY BEFORE, THAT THERE
6 ARE CURRENTLY SIX INSTITUTIONS THAT HAVE BOTH THE
7 BRIDGES AND COMPASS PROGRAMS. AND SO THERE'S SOME
8 OPPORTUNITIES HERE TO HELP INCREASE EFFICIENCIES FOR
9 THESE EXISTING PROGRAMS AND OPTIMIZE THAT TRAINING
10 EXPERIENCE. THERE'S ALSO AN OPPORTUNITY TO
11 INTEGRATE WITH CIRM'S INFRASTRUCTURE AND SCIENTIFIC
12 PROGRAMS AS WELL.

13 AND FINALLY, BASED ON SOME FEEDBACK WE'VE
14 GOTTEN FROM AWARDEES OVER THE YEARS, THERE'S SOME
15 OPPORTUNITIES TO NOT ONLY MAINTAIN THE CURRENT
16 PROGRAMS, BUT ALSO LEVERAGE EXISTING SYNERGIES.
17 THERE WILL BE AREAS THAT WE CAN IMPLEMENT ADDITIONAL
18 FLEXIBILITIES AND ALSO WAYS THAT WE CAN SIMPLIFY
19 ADMINISTRATIVE BURDENS FOR BOTH THE AWARDEE
20 INSTITUTION AS WELL AS CIRM INTERNAL MANAGEMENT OF
21 THESE PROGRAMS.

22 AND SO THAT BRINGS ME TO THE EDUC8
23 UMBRELLA PROGRAM THAT WE ARE INTRODUCING TO YOU
24 TODAY. SO EDUC8 IS AN UMBRELLA MECHANISM TO
25 SUPPORT, UPDATE, AND IMPROVE THE BRIDGES AND COMPASS

BETH C. DRAIN, CA CSR NO. 7152

1 PROGRAMS. AND THERE ARE THREE DIFFERENT PATHS THAT
2 AN INSTITUTION, AN APPLICANT CAN TAKE. SO THE
3 COMPASS, BRIDGES, OR DUAL PATH, WHICH I WILL EXPLAIN
4 IN DETAIL IN A COUPLE MORE SLIDES.

5 THE OBJECTIVE OF EDUC8 IS TO PREPARE
6 UNDERGRADUATE THROUGH MASTER'S LEVEL STUDENTS FOR
7 CAREERS IN REGENERATIVE MEDICINE BY IDENTIFYING AND
8 SUPPORTING UNTAPPED TALENT AND DEVELOPING
9 WELL-TRAINED, ADAPTABLE, AND COMMITTED PROFESSIONALS
10 FOR THE REGENERATIVE MEDICINE WORKFORCE.

11 THE APPROACH EDUC8 TAKES WILL BE FAMILIAR
12 TO MANY. SIMILAR TO COMPASS AND BRIDGES RIGHT NOW,
13 PROGRAMS WILL BE INTEGRATED INTO AN INSTITUTION'S
14 SPECIFIC DEGREE OR CERTIFICATE PROGRAM. THERE WILL
15 BE STRUCTURED MENTORSHIP AND PROFESSIONAL GUIDANCE.
16 SO TRAINEES WILL BE PARTICIPATING IN VERY SPECIFIC
17 COURSEWORK, VERY STRUCTURED MENTORING, AND
18 PROFESSIONAL DEVELOPMENT GUIDANCE.

19 OF COURSE, KEY TO THESE PROGRAMS IS THE
20 HANDS-ON EXPERIENCE IN THE FORM OF PAID INTERNSHIPS,
21 ACTIVITIES IN PATIENT AND COMMUNITY ENGAGEMENT, AS
22 WELL AS CIRM CONFERENCE ATTENDANCE.

23 NOW, THE HIGH LEVEL GOAL HERE IS PROMOTE
24 EXPLORATION AND EXPAND ACCESS TO CAREERS IN
25 REGENERATIVE MEDICINE FOR TRAINEES WHO ARE CURIOUS

BETH C. DRAIN, CA CSR NO. 7152

1 ABOUT BIOLOGY AND WANT TO EXPLORE THE OPPORTUNITIES
2 IN THESE FIELDS. ALSO IT'S TO PROMOTE EFFICIENT
3 TRANSITION TO CAREERS IN REGENERATIVE MEDICINE FOR
4 TRAINEES WHO ARE MORE COMMITTED TO A CERTAIN FIELD
5 AND WANT TO DIVERT AND TO START THEIR CAREERS.

6 OKAY. SO WHAT WE ARE KEEPING WITH EDUC8,
7 THESE ARE SOME REQUIRED ELEMENTS AND ACTIVITIES THAT
8 ARE IN THE CURRENT BRIDGES AND COMPASS PROGRAMS THAT
9 ARE WORKING GREAT. TRAINEE ACTIVITIES, TRAINEES
10 WILL STILL BE PARTICIPATING IN PATIENT/HEALTHCARE
11 ENGAGEMENT, COMMUNITY OUTREACH AND EDUCATION. AND
12 WE ARE NOW REQUIRING SCIENCE COMMUNICATION TO THE
13 PUBLIC AS AN ADDITIONAL WORKSHOP OR COURSE.

14 MENTORING AND PROFESSIONAL DEVELOPMENT AS WELL AS
15 PARTICIPATION IN A CIRM-RELATED TRAINEE CONFERENCE.
16 SOME ADMINISTRATIVE ACTIVITIES THAT WE ARE KEEPING
17 ARE THE INNOVATIVE AND STRATEGIC TRAINING
18 RECRUITMENT PLANS, ALUMNI TRACKING AND ENGAGEMENT,
19 MENTOR TRAINING, AND BEST PRACTICES, AS WELL AS
20 REQUIRED KNOWLEDGE AND RESOURCE SHARING BETWEEN
21 INSTITUTIONS AS WELL AS TO CIRM.

22 SOME OF THE ELEMENTS THAT WE ARE ADDING TO
23 EDUC8, SO FIRST, AS I MENTIONED, AN EXPANDED SCOPE
24 OF TYPES OF INTERNSHIPS. THIS IS CERTAINLY NOT A
25 COMPREHENSIVE LIST OF EXAMPLES, BUT SOME THESE

BETH C. DRAIN, CA CSR NO. 7152

1 EXAMPLES LISTED HERE WOULD BE PROJECT MANAGEMENT,
2 REGULATORY OR MANUFACTURING DESIGNS, PROCESS
3 DEVELOPMENT, DATA SCIENCE, AND COMPUTATIONAL
4 BIOLOGY.

5 WE'LL BE INSTILLING KEY SKILLSETS AND
6 COMPETENCIES, AND SOME OF THESE EXAMPLES LISTED HERE
7 INCLUDE TIME MANAGEMENT, PUBLIC SCIENTIFIC
8 COMMUNICATION, DATA SHARING, BIOETHICS, AND RESEARCH
9 ETHICS AS WELL.

10 WE'LL BE LEVERAGING INTER-PROGRAM
11 EFFICIENCIES. SO FOR INSTITUTIONS WHERE THIS IS
12 APPLICABLE, SOME EXAMPLES INCLUDE HAVING JOINT
13 ACTIVITIES FOR EARLY AND LATE STAGE TRAINING AND
14 OPPORTUNITIES FOR COLLABORATION WITH CIRM'S
15 INFRASTRUCTURE PROGRAMS, SUCH AS THE ALPHA CLINICS,
16 COMMUNITY CARE CENTERS OF EXCELLENCE, AND SHARED
17 RESOURCE LABS.

18 FINALLY, ADMINISTRATIVE EFFICIENCIES. SO
19 SOME EXAMPLES HERE ARE THAT UNDER THIS UMBRELLA
20 MECHANISM THERE WILL BE MORE UNIFIED GUIDANCE,
21 FASTER PROGRAM EXECUTION, AND LOWER ADMINISTRATIVE
22 BURDEN FOR BOTH THE AWARDEES AS WELL AS FOR CIRM'S
23 MANAGEMENT OF THESE PROGRAMS.

24 OKAY. SO THE OVERVIEW OF WHAT THE EDUC8
25 STRUCTURE LOOKS LIKE, IT IS MEANT TO ENABLE

BETH C. DRAIN, CA CSR NO. 7152

1 CONTINUOUS SUPPORT FOR BRIDGES AND COMPASS PROGRAMS
2 WITH AN ADDED OPPORTUNITY TO CREATE A FLEXIBLE AND
3 ACCELERATED PATH DEPENDING ON THE APPLICANT
4 INSTITUTION PROPOSAL. SO ON THE LEFT SOME OF THE
5 THINGS THAT AN APPLICANT MIGHT CONSIDER IS THE
6 TRAINEE TARGET. SO THIS WOULD BE THE EDUCATION
7 LEVEL AND THE TRAINING NEEDS OF THE TRAINEE
8 POPULATION. AND, OF COURSE, THE INSTITUTION'S
9 AVAILABLE RESOURCES AND ASSETS. AND ALL OF THAT
10 TAKEN INTO CONSIDERATION WILL HELP DETERMINE THE
11 PATH THAT ONE CAN TAKE UNDER THE EDUC8 MECHANISM.

12 SO ON THE RIGHT YOU'LL SEE THREE PATHS:
13 COMPASS, BRIDGES, AND A DUAL PATH. I'LL EXPLAIN IN
14 THE NEXT SLIDE WHAT THAT LOOKS LIKE.

15 OKAY. SO FOR COMPASS, COMPASS WILL
16 REMAIN -- WE'LL STILL BE SUPPORTING EARLY STAGE,
17 UNTAPPED TALENT. SO THIS REALLY IS TARGETED TO
18 STUDENTS WHO ARE CURIOUS ABOUT BIOLOGY BUT DON'T
19 QUITE KNOW WHAT THE OPPORTUNITIES THERE ARE. THESE
20 WILL BE TWO- TO THREE-MONTH INTERNSHIPS OVER
21 MULTIYEAR APPOINTMENTS, AND APPLICANT INSTITUTIONS
22 WILL BE THOSE WITH BACHELOR'S PROGRAMS.

23 THE BRIDGES PATH WILL CONTINUE TO SUPPORT
24 LATE STAGE, MORE CAREER-READY TRAINEES. THESE
25 TYPICALLY ARE TRAINEES WHO KNOW THEY WANT TO BE IN

BETH C. DRAIN, CA CSR NO. 7152

1 THE STEM AND BIOLOGY SPACE AND WANT TO GET SOME
2 EXPERIENCE IN ORDER TO JUMPSTART THEIR CAREERS UPON
3 GRADUATION. THESE TYPICALLY ARE SIX- TO 12-MONTH
4 INTERNSHIPS THAT ARE HELD EXTERNAL TO THE HOST
5 INSTITUTION. AND APPLICANT INSTITUTIONS ARE THOSE
6 WITHOUT A CIRM MAJOR FACILITY OR REGENERATIVE
7 MEDICINE RESEARCH INFRASTRUCTURE. SO THESE WOULD BE
8 CAL STATE UNIVERSITIES AND COMMUNITY COLLEGES.

9 NOW, THE DUAL PATH PROGRAM IS AN ADDED
10 OPPORTUNITY THAT CAN POTENTIALLY SUPPORT OR THAT CAN
11 SUPPORT, NOT POTENTIALLY, BOTH COMPASS AND BRIDGES
12 TYPE TRAINEES. BUT THERE IS A POTENTIAL HERE FOR
13 TRAINEES TO TRANSITION FROM A COMPASS TO BRIDGES
14 TYPE PROGRAM UNDER ONE MECHANISM. AS I MENTIONED
15 BEFORE, THE SIX INSTITUTIONS THAT CURRENTLY SUPPORT
16 BOTH COMPASS AND BRIDGES PROGRAMS, DEPENDING ON THE
17 SPECIFICS OF THE APPLICANT PROPOSAL, THERE COULD BE
18 AN OPPORTUNITY HERE TO STREAMLINE ANY DESIRE TO HAVE
19 TRAINEES START IN A COMPASS TYPE PROGRAM AND GO ON
20 INTO A BRIDGES TYPE PROGRAM WHERE THEY'RE MORE
21 TRANSITIONING TO A JOB-READY POSITION.

22 OKAY. THIS IS WHAT THE MAXIMUM AWARD
23 BUDGETS LOOK LIKE BASED ON CHOSEN PATH. SO ON THE
24 LEFT WE'RE LOOKING AT TOTAL AWARD COSTS OVER FIVE
25 YEARS OF THE GRANT. AND THE COLUMNS ARE BROKEN DOWN

BETH C. DRAIN, CA CSR NO. 7152

1 BY PATH. SO BRIDGES PATH, COMPASS PATH, AND DUAL
2 PATH. AND THESE NUMBERS ARE BASED ON A MAXIMUM OF
3 TEN TRAINEES PER YEAR OVER FIVE YEARS. NOW, THE
4 DIRECT COSTS FOR THE BRIDGES PATH WILL BE ABOUT 4.2
5 MILLION, FOR COMPASS JUST UNDER 3 MILLION, AND FOR
6 THE DUAL PATH ABOUT 6.4 MILLION. WITH OVERHEAD, THE
7 TOTAL AWARD AMOUNT FOR THE BRIDGES PATH COMES OUT TO
8 ABOUT 4.6 MILLION, COMPASS ABOUT 3.2 MILLION, AND
9 DUAL PATH ABOUT 6.9 MILLION.

10 THE PER TRAINEE INVESTMENT PER YEAR, AND
11 THIS IS LOOKING AT A MAXIMUM OF TEN TRAINEES PER
12 YEAR. KEEP IN MIND THAT, DEPENDING ON THE APPLICANT
13 PROPOSAL, THEY MAY NOT HIT THAT MAXIMUM OF TEN
14 BECAUSE IT'S JUST BASED ON THE PROJECTION OF A MAX
15 OF TEN TRAINEES PER YEAR. FOR BRIDGES, IT WOULD BE
16 91,000, COMPASS ABOUT 64,000, AND THE DUAL PATH,
17 DEPENDING ON THE PROPOSAL, WILL FALL SOMEWHERE
18 BETWEEN THOSE TWO RANGES. AND ALL OF THIS IS BASED
19 ON OUR GRANTS MANAGEMENT TEAM ANALYSIS OF TRUE
20 CATEGORICAL EXPENDITURE GROWTH AND CUMULATIVE CPI
21 PERCENT INCREASE SINCE 2021. AND THERE IS A
22 20-PERCENT INCREASE HERE FOR THE EDUC8 BUDGET
23 COMPARED TO THE CURRENT BRIDGES AND COMPASS AWARDS.

24 ALL RIGHT. SO THE TEAM AND INSTITUTION
25 ELIGIBILITY FOR EDUC8 LOOKS LIKE THIS. FIRST, FOR

BETH C. DRAIN, CA CSR NO. 7152

1 THE BRIDGES PATH, CAL STATE UNIVERSITIES AND
2 COMMUNITY COLLEGES WITH AN ACCREDITED CERTIFICATE,
3 UNDERGRADUATE, OR MASTER'S PROGRAMS IN A
4 BIOLOGY-RELEVANT DISCIPLINE. FOR THE COMPASS PATH,
5 ANY CALIFORNIA ACADEMIC INSTITUTION WITH AN
6 ACCREDITED BACHELOR'S DEGREE PROGRAM. WE ARE
7 REQUIRING THAT THE PROGRAM DIRECTOR MUST COMMIT AT
8 LEAST 5 PERCENT EFFORT. AND THE REQUIRED EXPERTISE
9 IS IN OUTREACH AND RECRUITMENT AS WELL AS
10 MENTORSHIP.

11 FOR DUAL PATH PROGRAMS, WE WILL BE
12 REQUIRING A CO-DIRECTOR WHO MUST ALSO COMMIT AT
13 LEAST 5 PERCENT EFFORT. AND THIS REALLY IS TO
14 ENSURE THAT DUAL PATH PROGRAMS ARE ABLE TO SMOOTHLY
15 RETAIN BOTH ELEMENTS OF TRAINEE TYPES AND
16 TRAINEE-TYPE ACTIVITIES. EACH INSTITUTION OR
17 APPLICANT MAY ONLY APPLY FOR ONE EDUC8 AWARD PER
18 CYCLE. AND WHAT I MEAN BY THAT IS WE ARE PROPOSING
19 TO RUN EDUC8 IN TWO CYCLES, ONE IN 2026 WHICH WILL
20 COVER THE OUTGOING BRIDGES PROGRAMS, AND AGAIN IN
21 2027 WHICH WILL COVER THE OUTGOING COMPASS PROGRAMS.
22 AND TWO CYCLES REALLY WILL CAPTURE UPDATES AND
23 IMPROVEMENTS FOR THESE EXISTING BRIDGES AND COMPASS
24 PROGRAMS, BUT ALSO PROVIDE A LONGER RUNWAY FOR ANY
25 NEW APPLICANT PROGRAMS TO COME IN.

BETH C. DRAIN, CA CSR NO. 7152

1 FINALLY, THERE'S ALSO A POSSIBILITY HAVING
2 TWO CYCLES WILL GIVE THE POSSIBILITY OF RESUBMISSION
3 FOR PROGRAMS THAT NEED IMPROVEMENT.

4 AND IN BREAKING DOWN, WE'RE LOOKING CLOSER
5 AT ONE CYCLE TIMELINE. PENDING BOARD APPROVAL IN
6 DECEMBER, APPLICATIONS WILL BE AVAILABLE EARLY
7 MARCH, DUE IN EARLY APRIL, THE APPLICATIONS WILL GO
8 TO THE GWG FOR REVIEW, AND AWARD CONTRACTING WILL
9 TAKE PLACE IN THE FALL OF 2026 FOR CYCLE ONE.

10 ALL RIGHT. SO IN SUMMARY, THE EDUC8
11 UMBRELLA PROGRAM WILL OFFER THREE DIFFERENT TYPES OF
12 PATHS: COMPASS TYPE, BRIDGES, OR DUAL PATH TRAINING
13 PROGRAM. IT WILL BE ANNUAL FOR TWO CYCLES IN 2026
14 AND 27. THE DURATION OF THE AWARD IS FIVE YEARS.
15 AND THE APPLICANTS ARE CALIFORNIA UNDERGRADUATE AND
16 MASTER'S INSTITUTIONS. THE LEADERSHIP AND EXPERTISE
17 REQUIRED IS A PROGRAM DIRECTOR AND MENTORSHIP AND
18 OUTREACH FACILITATORS. AND FOR DUAL PATH PROGRAMS,
19 A REQUIREMENT FOR A CO-DIRECTOR AS WELL. THE MAX
20 AWARD COST FOR BRIDGES PATH IS UP TO 4.6 MILLION,
21 FOR COMPASS UP TO 3.2 MILLION, AND FOR A DUAL PATH
22 UP TO 6.9 MILLION. THE NUMBER OF AWARDS PER YEAR
23 WILL BE 15 TO 18 AWARDS PER CYCLE. AND WE'RE
24 ANTICIPATING 1500 TO 2500 TRAINEES TO GO THROUGH
25 THESE PROGRAMS. THE MAX PROJECTION THAT WE'RE

BETH C. DRAIN, CA CSR NO. 7152

1 SEEING IS 99 MILLION PER CYCLE.

2 ALL RIGHT. SO THAT BRINGS ME TO THIS. WE
3 ARE REQUESTING THAT THE SCIENCE SUBCOMMITTEE
4 RECOMMEND APPROVAL OF THE PROPOSED EDUC8 TRAINING
5 PROGRAM TO THE ICOC WITH AN ALLOCATION OF 198
6 MILLION TO SUPPORT UP TO 36 AWARDS OVER TWO FUNDING
7 CYCLES. THIS WILL BE MAX 99 MILLION PER CYCLE. AND
8 IF THERE ARE UNSPENT FUNDS FROM CYCLE ONE, TO ROLL
9 OVER TO CYCLE TWO. WE'RE EXPECTING 1500 TO 2500
10 TRAINEES TO GO THROUGH THESE PROGRAMS. AND ABOUT
11 3.2 MILLION TO 6.9 MILLION PER INDIVIDUAL AWARD.

12 THAT IS WHAT I HAVE FOR EDUC8, AND I'M
13 HAPPY TO TAKE ANY COMMENTS OR QUESTIONS BEFORE I
14 JUMP INTO EDUC3.

15 CHAIRMAN FISCHER-COLBRIE: WITH THAT, I
16 THINK WE SHOULD ASK IF THERE'S ANY -- IF WE CAN GET
17 THIS APPROVED FOR A NOMINATION AND SECONDING.
18 ANYBODY?

19 VICVE CHAIR BONNEVILLE: SO MOVED.

20 CHAIRMAN FISCHER-COLBRIE: WITH THAT,
21 LET'S OPEN UP FOR DISCUSSION AMONGST THE COMMITTEE
22 AND THE TEAM.

23 MR. TOCHER: EXCUSE ME, MARK. I DON'T
24 BELIEVE I HEARD A SECOND.

25 CHAIRMAN IMBASCIANI: I SECOND.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. TOCHER: AND WHO WAS THE MAKER?

2 CHAIRMAN IMBASCIANI: MARIA.

3 MR. TOCHER: THANK YOU, MARK.

4 CHAIRMAN FISCHER-COLBRIE: THANK YOU.

5 WITH THAT, LET'S OPEN UP FOR QUESTIONS AND
6 DISCUSSION. I CAN'T SEE NECESSARILY ALL THE NAMES
7 THAT MIGHT HAVE THEIR HANDS RAISED. SO IF SOMEONE
8 CAN -- CLAUDETTE, IF YOU CAN TELL ME IF SOMEBODY'S
9 GOT THEIR HAND RAISED, THAT WOULD BE GREAT.

10 MR. TOCHER: WE DON'T SEE ANY HANDS AT THE
11 MOMENT.

12 CHAIRMAN FISCHER-COLBRIE: NO QUESTIONS
13 FROM THE SCIENCE COMMITTEE? OKAY. WITH THAT,
14 QUESTIONS FROM THE PUBLIC OR COMMENTS.

15 MS. MANDAC: FOR ALL MEMBERS OF THE
16 PUBLIC, YOU WILL EACH HAVE THREE MINUTES TO SPEAK.
17 WE DO KEEP TIME. AND WE WILL MUTE YOU AS SOON AS
18 THE THREE MINUTES IS UP. SO THE CLOCK STARTS NOW.

19 DR. BHATNAGA: SO THIS IS PARIJAT
20 BHATNAGA. I HAVE A QUESTION OR COMMENT REGARDING
21 THE EDUC8 PROGRAM AND THE ELIGIBILITY INSTITUTES.
22 IT WAS MENTIONED THAT ELIGIBLE INSTITUTES ARE THE
23 INSTITUTES OF HIGHER EDUCATION FOR THE BRIDGES AND
24 COMPASS. AND AT SOME POINT IT WAS ALSO MENTIONED
25 THAT BRIDGES IS ALSO -- THERE ARE CERTAIN ASPECTS

BETH C. DRAIN, CA CSR NO. 7152

1 THAT MAY NOT BE REQUIRED FOR, FOR EXAMPLE, TO BRIDGE
2 THE STUDENTS WHO MIGHT BE GETTING THE EXPERTISE AND
3 BRIDGING THEM FOR A JOB IN INDUSTRY OR SOMETHING
4 LIKE THAT.

5 SO IS THERE A REASON WHY AN INSTITUTE OF
6 HIGHER EDUCATION IS REQUIRED? ONLY THE ELIGIBLE
7 INSTITUTES ARE THE INSTITUTES OF HIGHER EDUCATION
8 AND NOT NECESSARILY ANOTHER PLACE LIKE MAYBE ANOTHER
9 NONPROFIT OR ANOTHER INDUSTRY THAT DO NOT EDUCATE,
10 DO NOT PROVIDE AN EDUCATION, BUT PROVIDE AN
11 OPPORTUNITY FOR THE STUDENTS TO GET THE TRAINING?

12 CHAIRMAN FISCHER-COLBRIE: OKAY. DAISY,
13 DO YOU WANT TO TAKE THAT QUESTION?

14 MS. XIN: YEAH. SO THE ELIGIBILITY IS FOR
15 CALIFORNIA-BASED INSTITUTIONS OR NONPROFIT
16 INSTITUTIONS -- LET ME JUST PAUSE MY SCREEN. ONE
17 SECOND. SORRY ABOUT THAT. I'M HAVING SOME
18 TECHNICAL ISSUES OVER HERE. I DON'T KNOW, KELLY, DO
19 YOU WANT TO QUICKLY ANSWER HIS QUESTION WHILE I'M
20 FIGURING OUT THE SCREEN?

21 DR. SHEPARD: I CAN STEP IN. SURE. SO
22 THE BRIDGES PROGRAM IS TARGETED AT CAL STATE
23 UNIVERSITIES AND COMMUNITY COLLEGES WHICH CAN
24 INCLUDE JUNIOR COLLEGES. BUT WHAT'S REQUIRED IS
25 THAT THERE IS A CERTIFICATE PROGRAM OR SOME KIND OF

BETH C. DRAIN, CA CSR NO. 7152

1 DEGREE PROGRAM, FOR EXAMPLE, A BACHELOR'S,
2 ASSOCIATE, OR MASTER'S, THAT THE BRIDGES TRAINING
3 CAN BE INTEGRATED WITHIN. SO THAT MEANS THERE'S
4 ALREADY A BIOLOGY CERTIFICATE OR DEGREE PROGRAM.
5 AND THEN THE BRIDGES PROGRAM PROVIDES FUNDING TO
6 SUPPORT THE REGENERATIVE MEDICINE COMPONENTS, AND IT
7 SUPPORTS THE PATIENT ENGAGEMENT ACTIVITIES, BUT MOST
8 IMPORTANTLY, IT SUPPORTS A PAID INTERNSHIP WHICH IN
9 THE BRIDGES PROGRAM HAS TO BE EXTERNAL TO THE
10 INSTITUTION BECAUSE CAL STATE UNIVERSITIES AND
11 COMMUNITY COLLEGES DON'T HAVE HIGHLY FUNDED FEDERAL
12 RESEARCH INFRASTRUCTURE OR CIRM-FUNDED RESEARCH
13 INFRASTRUCTURE TO SUPPORT THE MOST CUTTING-EDGE GENE
14 THERAPY AND STEM CELL TREATMENTS AND BIOLOGY.

15 SO THE BRIDGES PROGRAM PROVIDES A BRIDGE
16 OR OPPORTUNITY TO CONNECT THOSE STUDENTS IN THESE
17 OTHER PLACES TO THESE WORLD-CLASS LABS WHICH ARE AT
18 THE MAJOR RESEARCH INSTITUTIONS AROUND THE STATE,
19 INCLUDING SOME OF THOSE WITH MEDICAL SCHOOLS. SO
20 THAT IS WHY BRIDGES PROGRAMS ARE TARGETED TO THOSE
21 INSTITUTIONS.

22 COMPASS PROGRAMS ARE TARGETED TO ANY
23 INSTITUTION THAT HAS AN ACCREDITED BACHELOR'S DEGREE
24 PROGRAM. AND THAT'S BECAUSE THAT PROGRAM IS REALLY
25 TRYING TO TARGET STUDENTS WHO HAVE AN APTITUDE AND

BETH C. DRAIN, CA CSR NO. 7152

1 INTEREST IN SCIENCE BUT MAY NOT HAVE HAD THE
2 RESOURCES IN ORDER TO KNOW OF ALL THE POSSIBLE
3 CAREERS THAT WOULD BE AVAILABLE TO THEM AND MAY NOT
4 HAVE HAD EXPOSURE TO AN ENVIRONMENT THAT CAN PROVIDE
5 THOSE SKILLSETS. AND SO THOSE -- THAT IS WHY WE
6 REQUIRE A BACHELOR'S PROGRAM AT THOSE INSTITUTIONS.

7 BUT COMPASS PROGRAMS ALSO HAVE TO BE ABLE
8 TO PROVIDE KIND OF THE WORLD-CLASS RESEARCH TRAINING
9 OPPORTUNITY FOR INTERNSHIPS AS WELL, WHICH ARE FOUND
10 IN THOSE MAJOR UNIVERSITIES THAT OFFER PH.D.
11 PROGRAMS AND HAVE MEDICAL SCHOOLS. SO THEY DON'T
12 NECESSARILY HAVE TO GO SOMEWHERE ELSE TO DO THEIR
13 INTERNSHIP, WHICH IS WHAT YOU DO HAVE TO DO WITH A
14 BRIDGES GRANT.

15 DID THAT ANSWER YOUR QUESTION?

16 DR. BHATNAGA: MAYBE I CAN ASK A MORE
17 DIRECT QUESTION ON THE ELIGIBILITY. IT DOES ANSWER
18 THE QUESTION, BUT IT DOESN'T VERIFY THE INTENTION
19 HOW -- THE REASONING BEHIND CREATION OF THESE
20 PROGRAMS. SO JUST LIKE THE MORE DIRECT QUESTION IS
21 THAT I HAVE STARTED A NONPROFIT RESEARCH
22 ORGANIZATION, AND I HAVE BEEN PREVIOUSLY FUNDED BY
23 NIH AND DARPA FOR LAST TEN YEARS, AND I HAVE
24 PUBLISHED IN WORLD-CLASS JOURNALS. AND SINCE THE
25 NONPROFIT IS NEW, I DON'T HAVE THE FUNDS TO -- I'M

BETH C. DRAIN, CA CSR NO. 7152

1 NOT AFFILIATED WITH AN EDUCATION INSTITUTE, BUT
2 UNDER MY MENTORSHIP ANY STUDENT WOULD GET A
3 WORLD-CLASS OPPORTUNITY TO GET TRAINING IN
4 REGENERATIVE MEDICINE, GENE THERAPY, CELL THERAPY.

5 SO IS THERE ANY REASON WHY A NONPROFIT
6 THAT IS NOT AFFILIATED WITH AN EDUCATIONAL INSTITUTE
7 THAT DOESN'T HAVE A DEGREE PROGRAM IS INELIGIBLE TO
8 PROVIDE SUCH TRAINING OPPORTUNITIES TO THE STUDENTS?
9 IF SOMETHING LIKE THIS IS MADE AVAILABLE TO A
10 NONPROFIT LIKE MINE, IT WILL BE A GREAT OPPORTUNITY
11 FOR THE STUDENTS AS WELL AS IT WILL BE A GREAT
12 OPPORTUNITY FOR A NONPROFIT TO DO CUTTING-EDGE
13 RESEARCH WITH NEW MANPOWER.

14 DR. SHEPARD: NONPROFIT RESEARCH
15 INSTITUTIONS CAN HOST TRAINEES FROM THESE PROGRAMS.
16 YOU WOULD NEED TO PARTNER WITH ONE OF THEM.

17 DR. BHATNAGA: OKAY. SO EDUCATIONAL
18 PARTNERING AND EDUCATION --

19 DR. SHEPARD: DO I NEED TO MOVE ON, OR
20 SHOULD I FINISH ANSWERING?

21 CHAIRMAN FISCHER-COLBRIE: FINISH THE
22 THOUGHT.

23 DR. SHEPARD: OKAY. THE APPLICANT
24 INSTITUTION, THE ONE WHO HOLDS THE GRANT, HAS TO BE
25 AN ACCREDITED EDUCATIONAL INSTITUTION. BUT THE

BETH C. DRAIN, CA CSR NO. 7152

1 INTERNS, FOR EXAMPLE, BRIDGES INTERNS, THEY GO AND
2 WORK IN LABS AT OTHER PLACES. AND IF YOU HAVE AN
3 APPROPRIATE ENVIRONMENT, YOU CAN CONNECT WITH AN
4 EXISTING BRIDGES PROGRAM OR A FUTURE BRIDGES
5 PROGRAM. AND IF YOU HAVE THE APPROPRIATE LEVEL OF
6 MENTORSHIP THAT CAN BE PROVIDED AND APPROPRIATE
7 RESOURCES AND STABILITY, THEN YOU CAN DISCUSS WITH
8 THOSE DIRECTORS THE OPTION OF TRAINING STUDENTS
9 THERE IN YOUR FACILITY.

10 CHAIRMAN FISCHER-COLBRIE: GREAT. LET'S
11 GO ON TO THE NEXT PERSON. THANK YOU, KELLY, FOR
12 THAT COGENT ANSWER. CLAUDETTE, IS THERE ANOTHER
13 COMMENT?

14 MS. MANDAC: NO, THERE ARE NO ADDITIONAL
15 HANDS RAISED.

16 CHAIRMAN FISCHER-COLBRIE: OKAY. WITH
17 THAT, WHY DON'T WE PROCEED TO A VOTE.

18 MR. TOCHER: GREAT. THANKS VERY MUCH.
19 MARIA BONNEVILLE.

20 VICE CHAIR BONNEVILLE: YES.

21 MR. TOCHER: MONICA CARSON.

22 DR. CARSON: YES.

23 MR. TOCHER: MARK FISCHER-COLBRIE.

24 CHAIRMAN FISCHER-COLBRIE: YES.

25 MR. TOCHER: ELENA FLOWERS.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. FLOWERS: YES.
2 MR. TOCHER: JUDY GASSON.
3 DR. GASSON: YES.
4 MR. TOCHER: VITO IMBASCIANI.
5 CHAIRMAN IMBASCIANI: YES.
6 MR. TOCHER: PAT LEVITT.
7 DR. LEVITT: YES.
8 MR. TOCHER: SHLOMO MELMED. SORRY,
9 SHLOMO? I'LL COME BACK. CAROLYN MELTZER.
10 DR. MELTZER: YES.
11 MR. TOCHER: CHRIS MIASKOWSKI.
12 DR. MIASKOWSKI: YES.
13 MR. TOCHER: KAROL WATSON.
14 DR. WATSON: YES.
15 MR. TOCHER: AND KEITH YAMAMOTO.
16 DR. YAMAMOTO: YES.
17 MR. TOCHER: GREAT. I UNDERSTAND SHLOMO
18 HAS DROPPED FROM THE CALL FOR NOW. SO THE MOTION
19 CARRIES. THANK YOU, MARK.
20 CHAIRMAN FISCHER-COLBRIE: THANK YOU,
21 SCOTT. WITH THAT, LET'S MOVE ON TO THE NEXT AGENDA
22 ITEM, WHICH IS CONSIDERATION OF THE EDUC3 SPARK
23 PROGRAM. AND, DAISY, IF YOU COULD LEAD THE
24 DISCUSSION ON THAT, THAT WOULD BE GREAT.
25 MS. XIN: SOUNDS GOOD. LET'S JUMP OVER TO

BETH C. DRAIN, CA CSR NO. 7152

1 SPARK. AND I'M STILL SCREEN SHARING, RIGHT? I'M
2 HAVING SLIGHT TECHNICAL ISSUES, BUT HOPEFULLY THIS
3 IS GOING THROUGH FOR EVERYONE.

4 CHAIRMAN FISCHER-COLBRIE: WE CAN SEE YOUR
5 SCREEN.

6 MS. XIN: EXCELLENT. ALL RIGHT. SO THE
7 EDUC3 SPARK CONCEPT PRESENTATION, LET'S JUMP RIGHT
8 INTO IT. SO SIMILARLY, WHAT YOU CAN EXPECT IS A
9 BRIEF BACKGROUND OF THE SPARK PROGRAM, DETAILS ABOUT
10 THE EDUC3 CONCEPT, ENDING WITH SIMILAR TIMELINE AND
11 AWARD SUMMARY AND REQUEST FOR MOTION.

12 SO ONCE AGAIN, THE SAF GOAL 6
13 RECOMMENDATION, ONE OF THE RECOMMENDATIONS IS TO
14 DEVELOP PROGRAMMING IN ORDER TO SUPPORT OUTREACH
15 EDUCATION EFFORTS FOR K THROUGH 12 STUDENTS,
16 TEACHERS, AND COMMUNITY MEMBERS VIA COLLABORATION.
17 AND TO THIS END WE ARE PROPOSING TO RELAUNCH THE
18 EDUC3 OR SPARK PROGRAM.

19 NOW, THE SPARK PROGRAM IS A PROGRAM FOR
20 HIGH SCHOOL STUDENTS THAT INTEGRATES WITH AN
21 EXISTING SUMMER HIGH SCHOOL PROGRAM AT CALIFORNIA
22 INSTITUTIONS ACROSS THE STATE. AND IT PROVIDES PAID
23 SUMMER INTERNSHIPS, TYPICALLY SIX TO TEN WEEKS IN
24 LENGTH, IN THE STEM CELL AND GENE THERAPY RESEARCH
25 LABS AT THESE INSTITUTIONS. STUDENTS ALSO

BETH C. DRAIN, CA CSR NO. 7152

1 PARTICIPATE IN PREP COURSES AND WORKSHOPS THAT ARE
2 RELEVANT TO THEIR INTERNSHIPS. THEY ALSO ARE A PART
3 OF ACTIVITIES IN PATIENT ENGAGEMENT AND COMMUNITY
4 OUTREACH AND PARTICIPATE IN AN ANNUAL SPARK
5 CONFERENCE. AND THESE PICTURES ARE ACTUALLY FROM
6 OUR SPARK TRAINING CONFERENCE THIS YEAR IN SAN
7 DIEGO.

8 SO AS I MENTIONED, SPARK TRAINS HIGH
9 SCHOOL STUDENTS. AND THE CURRENT AWARDS, WE HAVE 11
10 ACTIVE PROGRAMS ACROSS CALIFORNIA LISTED HERE. AND
11 SPARK STUDENTS REALLY ARE QUITE AMAZING IN THE SENSE
12 THAT THEY'RE HIGH SCHOOL STUDENTS, BUT THEY REALLY
13 GET A LOT OUT OF THESE INTERNSHIPS. AND THIS IS
14 JUST AN EXAMPLE OF ONE OF MANY STORIES THAT WE HEAR.
15 THIS IS SARANYA. SHE DID AN INTERNSHIP AT SANFORD
16 BURNHAM. AND ORIGINALLY SHE WAS MOTIVATED BY FAMILY
17 HEALTH CHALLENGES. SHE HAD ENTERED THE PROGRAM WITH
18 UNCERTAINTY, BUT NOW SHE'S ACTUALLY PURSUING
19 IMMUNOLOGY AND NEUROSCIENCE.

20 THE HIGH LEVEL IMPACT THAT WE'VE SEEN IN
21 SPARK OVER THE YEARS, WE'VE HAD OVER 950 STUDENTS
22 THAT HAVE BEEN TRAINED THROUGH THE SPARK PROGRAM.
23 AND OF THOSE TRACKED, 93 PERCENT OF THEM REPORT
24 PURSUING STEM PATH AFTER CONCLUSION OF THE PROGRAM.

25 THE OBJECTIVES OF EDUC3 OR SPARK IS TO

BETH C. DRAIN, CA CSR NO. 7152

1 INSPIRE, EDUCATE, AND MOTIVATE HIGH SCHOOL STUDENTS
2 TO BECOME INVOLVED IN CIRM'S MISSION AND ALSO TO
3 PROVIDE SUMMER TRAINING OPPORTUNITIES AND BROAD
4 PARTICIPATION IN THE STEM CELL, GENE THERAPY, AND
5 RELATED RESEARCH SPACE TO HIGH SCHOOL STUDENTS,
6 ESPECIALLY THOSE WHO MIGHT NOT OTHERWISE HAVE
7 OPPORTUNITIES FOR THESE TYPES OF INTERNSHIPS DUE TO
8 SOCIAL, GEOGRAPHIC, OR OTHER CONSTRAINTS.

9 NOW, THE SCOPE AND STRUCTURE OF SPARK
10 IS -- EACH PROGRAM WILL STILL BE LED BY A QUALIFIED
11 PROGRAM DIRECTOR WHO WILL BE MANAGING AND
12 COORDINATING ALL ACTIVITIES SUPPORTED BY THE
13 PROGRAM. WE ARE KEEPING THESE COMPONENTS. SO, OF
14 COURSE, THE MAIN SUMMER INTERNSHIP WHERE TRAINEES
15 WILL BE PARTICIPATING IN HANDS-ON REGENERATIVE
16 MEDICINE RESEARCH IN HOST LABS AT THE APPLICANT
17 INSTITUTION OR A PARTNERING ORGANIZATION. THEY WILL
18 ALSO BE PARTICIPATING IN AUXILIARY EDUCATIONAL
19 ACTIVITIES AS THESE ARE ADDITIONAL CONTENT OR
20 CLASSES THAT SUPPORT THE RESEARCH INTERNSHIP.

21 (PAUSE IN PROCEEDINGS.)

22 MS. XIN: ALL RIGHT. I'M GOOD.
23 ADDITIONALLY, THEY WILL STILL BE PARTICIPATING IN
24 PATIENT AND HEALTHCARE ENGAGEMENT ACTIVITIES,
25 COMMUNITY OUTREACH, AND EDUCATION. WE WILL STILL BE

BETH C. DRAIN, CA CSR NO. 7152

1 REQUIRING AN ALUMNI TRACKING PLAN, AND TRAINEES WILL
2 ALSO PARTICIPATE IN A CIRM-RELATED CONFERENCE.

3 WHAT WE ARE ADDING, THERE WILL BE AN
4 EXPANDED SCOPE OF INTERNSHIP POSSIBILITIES. SO SOME
5 EXAMPLES ARE IN THE MANUFACTURING SPACE, QUALITY,
6 DATA SCIENCE OR BIOINFORMATICS, AND OTHER
7 DISCIPLINES THAT ARE RELEVANT. WE WILL BE
8 ENCOURAGING AND LEVERAGING PARTNERSHIPS WITH CIRM
9 INFRASTRUCTURE PROGRAMS AND REQUIRING RESOURCE AND
10 KNOWLEDGE SHARING.

11 THE INSTITUTION ELIGIBILITY ARE CALIFORNIA
12 PUBLIC UNIVERSITIES OR COLLEGES OR PRIVATE NONPROFIT
13 ACADEMIC INSTITUTIONS ACCREDITED BY THE WESTERN
14 ASSOCIATION OF SCHOOLS AND COLLEGES. OTHER
15 INSTITUTIONS WITH A DOCUMENTED TRACK RECORD OF
16 DELIVERING LAB-BASED RESEARCH TRAINING TO HIGH
17 SCHOOL STUDENTS.

18 DR. CANET-AVILES: DAISY, COULD YOU ASK
19 KELLY TO CONTINUE? WOULD THAT BE OKAY? CAN YOU
20 CONTINUE?

21 MS. XIN: YEAH.

22 DR. CANET-AVILES: I'M FEELING BAD FOR
23 YOU. KELLY, CAN YOU CONTINUE?

24 DR. SHEPARD: SURE. AS DAISY JUST
25 MENTIONED, THE ELIGIBLE INSTITUTIONS, IN ADDITION TO

BETH C. DRAIN, CA CSR NO. 7152

1 THOSE OTHER CALIFORNIA INSTITUTIONS THAT HAVE A
2 DOCUMENTED TRACK RECORD OF SUCCESSFULLY DELIVERING
3 LABORATORY-BASED RESEARCH TRAINING TO HIGH SCHOOL
4 STUDENTS WOULD ALSO BE ELIGIBLE AND WELCOME TO
5 APPLY. WE DO ASK THAT PROGRAMS HAVE AN EXISTING
6 HIGH SCHOOL INTERNSHIP OR HAVE HAD ONE WITHIN THE
7 PAST TWO YEARS AT THE TIME OF APPLICATION SO THAT
8 THIS PROGRAM CAN BE INTEGRATED WITHIN THAT.

9 THE PROGRAM DIRECTOR SHOULD HAVE RELEVANT
10 EXPERIENCE TO LEADING A PROGRAM OF THIS NATURE. IF
11 AN APPLICANT CHOOSES TO WORK WITH A PARTNERING
12 ORGANIZATION THAT CAN HOST TRAINEES, THAT PARTNERING
13 SITE MUST HAVE APPROPRIATE PERSONNEL AND FACILITIES
14 TO ACCOMMODATE HIGH SCHOOL STUDENTS AND WORK AROUND
15 THEIR NEEDS. AND SIMILARLY WITH THE EDUC8 PROGRAM,
16 AN APPLICANT MAY SUBMIT A SINGLE EDUC3 APPLICATION.
17 NEXT SLIDE PLEASE.

18 AND THIS IS JUST HOW THE AWARDS ARE
19 BUDGETED. SO SIMILARLY TO WHAT WE DISCUSSED WITH
20 EDUC8, THE AWARD CAPS WERE ADJUSTED RELATIVE TO OUR
21 CURRENT PROGRAM BASED ON OUR GRANTS MANAGEMENT
22 TEAM'S ANALYSIS OF CATEGORICAL EXPENDITURE GROWTH
23 AND CUMULATIVE CPI INCREASE. SO THE TRAINEE
24 STIPENDS WOULD BE \$5500. THEY'RE PROVIDED A TRAVEL
25 ALLOWANCE TO THE ANNUAL CONFERENCE. SO IN OTHER

BETH C. DRAIN, CA CSR NO. 7152

1 WORDS, THE DIRECT COST PER TRAINEE IS 6500. THERE'S
2 A PROGRAM ADMIN ALLOWANCE ALSO CALCULATED ON A PER
3 TRAINEE BASIS. WITH THE OVERHEADS, THIS MAKES FOR A
4 TOTAL AWARD AMOUNT OF \$704,000. NEXT SLIDE PLEASE.

5 AND THIS WOULD BE THE TIMELINE. SO THE
6 CURRENT SPARK PROGRAMS HAVE SUFFICIENT FUNDING TO
7 PROVIDE SUPPORT FOR ONE MORE SUMMER. SO THEY WILL
8 BE RUNNING THROUGH THE SUMMER OF 2026. HOWEVER, IN
9 ORDER FOR CONTINUITY AND FOR NEW PROGRAMS TO BEGIN
10 IN SUMMER OF 2027, THE AWARDS WOULD NEED TO BE
11 INITIATED AT THE END OF 2026. SO THE PROPOSED
12 TIMELINE HERE FOLLOWING THE CONCEPT APPROVAL THAT WE
13 WOULD HOPE WOULD HAPPEN IN DECEMBER, APPLICATIONS
14 WOULD BECOME AVAILABLE IN EARLY MARCH. AND
15 APPLICATIONS WOULD BE DUE IN THE SPRING OR SO, AND
16 THE REVIEW WOULD BE HAPPENING IN THE SUMMER WITH THE
17 ARS MEETING HAPPENING IN OCTOBER OR FALL. NEXT
18 SLIDE PLEASE.

19 SO IN SUMMARY, WE ARE ASKING FOR SUPPORT
20 OF AN UPDATED EDUC3 SPARK CONCEPT. IT WOULD RECUR
21 ONE CYCLE. SO NOT RECUR. SO IT WOULD BE OFFERED AS
22 A SINGLE CYCLE IN 2026. IT WOULD SUPPORT PROGRAMS
23 FOR FIVE YEARS. IT'S OFFERED TO CALIFORNIA-BASED
24 INSTITUTIONS. EACH AWARD IS CAPPED AT \$704,000
25 TOTAL. WE ANTICIPATE MAKING ABOUT 12 AWARDS WHICH

BETH C. DRAIN, CA CSR NO. 7152

1 WOULD FACTOR INTO APPROXIMATELY 720 ADDITIONAL HIGH
2 SCHOOL STUDENTS THAT COULD BE TRAINED THROUGH THIS
3 PROGRAM. SO THE AMOUNT OF FUNDING THAT WOULD BE
4 REQUIRED TO SUPPORT 12 NEW PROGRAMS WOULD BE \$8.5
5 MILLION.

6 AND FOR THIS LAST SLIDE, CIRM RESPECTFULLY
7 REQUESTS THE SCIENCE SUBCOMMITTEE RECOMMEND APPROVAL
8 OF THE PROPOSED SPARK TRAINING PROGRAM TO THE ICOC
9 WITH AN ALLOCATION OF \$8.5 MILLION WHICH WOULD
10 SUPPORT UP TO 12 SPARK AWARDS, EACH WITH A FIVE-YEAR
11 DURATION. THIS WOULD PROVIDE SUPPORT FOR 720
12 TRAINEES TO HAVE SUMMER INTERNSHIPS, AND THE AWARD
13 AMOUNT PER INSTITUTION WOULD BE \$704,000.

14 AND WITH THAT, I'M HAPPY TO TAKE QUESTIONS
15 OR IF DAISY IS READY TO STEP IN.

16 CHAIRMAN FISCHER-COLBRIE: LET'S START
17 WITH A REQUEST FOR A MOTION AND A SECOND. CAN I GET
18 A MOTION FOR APPROVAL?

19 DR. YAMAMOTO: SO MOVED.

20 CHAIRMAN FISCHER-COLBRIE: KEITH HAS
21 MOVED. COULD SOMEBODY STEP IN FOR A SECOND?

22 DR. MELTZER: SECOND.

23 CHAIRMAN FISCHER-COLBRIE: THANK YOU,
24 CAROLYN. WITH THAT, LET'S OPEN IT UP FOR ANY
25 QUESTIONS BY THE COMMITTEE OR COMMENTS. I'M NOT

BETH C. DRAIN, CA CSR NO. 7152

1 SEEING ANY.

2 MR. TOCHER: KEITH HAD HIS HAND RAISED,
3 KEITH YAMAMOTO.

4 CHAIRMAN FISCHER-COLBRIE: THANK YOU.
5 KEITH.

6 DR. YAMAMOTO: THANKS FOR THIS, KELLY AND
7 DAISY. I HAD A QUESTION ABOUT THE ADMINISTRATION
8 COSTS. SO THE ADMINISTRATION COSTS OF 4167 AND
9 INDIRECT COSTS AS WELL. SO WHAT'S THE DISTINCTION
10 BETWEEN ADMINISTRATIVE COSTS AND INDIRECT COSTS?
11 AND WHAT IS THE -- HOW WAS THAT ADMINISTRATIVE COST
12 CALCULATED? WHAT DO YOU GET FROM THAT BECAUSE THE
13 TOTAL INDIRECT COSTS OR THE TOTAL COSTS IN ADDITION
14 TO THE DIRECT COSTS ARE QUITE SUBSTANTIAL?

15 DR. SHEPARD: RIGHT. SO THE ADMIN PROGRAM
16 AND ADMINISTRATIVE COSTS ARE THE COST THAT
17 SUPPORTS THE -- IT PROVIDES SALARY SUPPORT FOR SOME
18 OF THE ADMINISTRATORS WHO ARE RUNNING THE AWARDS.
19 IT'S SUPPORTING THE PATIENT ENGAGEMENT AND THE
20 COMMUNITY OUTREACH ACTIVITIES THAT THEY'RE DOING.
21 SO IT'S DIRECT PROJECT COSTS AS WELL. IT'S JUST NOT
22 TIED TO AN INDIVIDUAL TRAINEE. SO THE STIPENDS, AND
23 THESE ARE UP-TO AMOUNTS, NOT ALL PROGRAMS PROVIDE
24 THE MAXIMUM AMOUNT, BUT SOME DO. AND SO THE
25 INDIRECT COSTS ARE MORE TRADITIONAL WHAT YOU THINK

BETH C. DRAIN, CA CSR NO. 7152

1 OF AS IDC'S THAT GO TO THE INSTITUTION. AND THAT'S
2 10 PERCENT.

3 DR. YAMAMOTO: GOT IT. GOOD. THANK YOU.

4 DR. SHEPARD: UH-HUH.

5 CHAIRMAN FISCHER-COLBRIE: ARE THERE
6 QUESTIONS FROM THE COMMITTEE? OKAY. WITH THAT,
7 LET'S OPEN IT UP TO ANY COMMENTS OR QUESTIONS FROM
8 THE PUBLIC.

9 MS. MANDAC: THERE ARE NO HANDS RAISED,
10 MARK.

11 CHAIRMAN FISCHER-COLBRIE: GREAT. SCOTT,
12 IF WE COULD PROCEED WITH A VOTE.

13 MR. TOCHER: SURE. MARIA BONNEVILLE.

14 VICE CHAIR BONNEVILLE: YES.

15 MR. TOCHER: MONICA CARSON.

16 DR. CARSON: YES.

17 MR. TOCHER: MARK FISCHER-COLBRIE.

18 CHAIRMAN FISCHER-COLBRIE: YES.

19 MR. TOCHER: ELENA FLOWERS.

20 DR. FLOWERS: YES.

21 MR. TOCHER: JUDY GASSON.

22 DR. GASSON: YES.

23 MR. TOCHER: VITO IMBASCIANI.

24 CHAIRMAN IMBASCIANI: I'M YES.

25 MR. TOCHER: PAT LEVITT.

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

DR. LEVITT: YES.
MR. TOCHER: SHLOMO MELMED. CAROLYN
MELTZER.
DR. MELTZER: YES.
MR. TOCHER: CHRIS MIASKOWSKI.
DR. MIASKOWSKI: YES.
MR. TOCHER: KAROL WATSON.
DR. WATSON: YES.
MR. TOCHER: AND KEITH YAMAMOTO.
DR. YAMAMOTO: YES.
MR. TOCHER: THANK YOU VERY MUCH, MARK.

THE MOTION CARRIES.

CHAIRMAN FISCHER-COLBRIE: GREAT. WITH
THAT, I'M GOING TO TURN THE MEETING OVER TO LIZ.
AND LIZ, IF YOU COULD INTRODUCE YOURSELF AND BRING
UP THE NEXT AGENDA ITEM.

DR. NOBLIN: YEAH, OF COURSE. THANK YOU
SO MUCH, MARK. IF I COULD JUST GET A CONFIRMATION
THAT THE SLIDES ARE COMING THROUGH.

CHAIRMAN FISCHER-COLBRIE: YES.

DR. NOBLIN: FANTASTIC. SO GOOD
AFTERNOON, EVERYONE. MY NAME IS LIZ NOBLIN. I'M A
CIRM FELLOW FOR PROGRAM DEVELOPMENT. AND TODAY I'M
GOING TO BE SHARING WITH YOU AN UPDATE ON HOW THE
CIRM TEAM STRUCTURES AND PRESENTS FUNDING

BETH C. DRAIN, CA CSR NO. 7152

1 RECOMMENDATIONS FOR THE APPLICATION REVIEW
2 SUBCOMMITTEE.

3 SO WHY IS THIS COMING TODAY? FIRST,
4 ACKNOWLEDGING THAT MANY OF THE MEMBERS HERE ALSO DO
5 SERVE ON THE APPLICATION REVIEW SUBCOMMITTEE, AND
6 THAT COMMITTEE VERY SOON ON DECEMBER 11TH IS GOING
7 TO BE SEEING THE FIRST ROUND OF APPLICATIONS THAT
8 HAVE COME THROUGH THE UPDATED CLIN2 PROGRAM AND THE
9 NEWLY LAUNCHED PRECLINICAL DEVELOPMENT PROGRAM.

10 SO TODAY WE WANTED TO PRESENT SOME
11 INFORMATION TO HELP YOU ANTICIPATE WHAT YOU WILL SEE
12 AT THAT DECEMBER 11TH MEETING.

13 AND THEN FINALLY, I'D JUST LIKE TO
14 ACKNOWLEDGE THAT THIS UPDATE HAS BEEN A CIRM-WIDE
15 COLLABORATION UNDER THE DIRECTION OF GIL AND ROSA,
16 BUT WITH CRITICAL INPUT FROM PROGRAM TEAM AND REVIEW
17 TEAM COLLEAGUES AND ALSO OUR BOARD GOVERNANCE
18 COLLEAGUES.

19 SO WITH THAT IN THIS BRIEF PRESENTATION
20 TODAY WE'LL COVER THREE MAIN TOPICS. THE FIRST IS
21 WHAT ARE OUR GOALS AND OBJECTIVES FOR REALLY
22 REFINING BEST PRACTICES AND THE STRUCTURE FOR
23 DELIVERING CIRM RECOMMENDATIONS. THEN WE'LL GO OVER
24 WHAT ARE THE CIRCUMSTANCES AND THE PARAMETERS ON
25 WHICH CIRM WOULD BASE RECOMMENDATIONS. AND THEN,

BETH C. DRAIN, CA CSR NO. 7152

1 FINALLY, A LOOK AHEAD TO THE RESOURCES AND THE
2 FORMAT OF HOW THESE WILL BE PRESENTED TO THE
3 APPLICATION REVIEW SUBCOMMITTEE FOR YOUR FUNDING
4 DECISIONS.

5 SO TO REITERATE, WHAT YOU ARE GOING TO SEE
6 TODAY IS REALLY A REFINEMENT OF EXISTING AND
7 HISTORICAL PRACTICES THAT CIRM HAS USED IN MANY
8 INSTANCES TO MAKE FUNDING RECOMMENDATIONS IN
9 ADDITION TO THE RECOMMENDATIONS THAT YOU SEE FROM
10 GRANTS WORKING GROUP OR OTHER REVIEW WORKING GROUPS.
11 SO TODAY, AGAIN, THIS IS IN ANTICIPATION OF THE
12 FIRST ROUND OF SCIENTIFIC APPLICATIONS THAT ARE
13 GOING TO BE COMING THROUGH. WE HAVE DEVELOPED MORE
14 STANDARDIZED GUIDELINES FOR FORMING THOSE
15 RECOMMENDATIONS AS WELL AS STANDARDIZED TEMPLATES
16 FOR SHARING THAT INFORMATION WITH THE ARS TO AID IN
17 MAKING WELL-INFORMED FUNDING DECISIONS.

18 SO THE FRAMEWORK TODAY HAS TWO MAIN AIMS.
19 THESE ARE TO STANDARDIZE GUIDELINES AND OUTPUTS
20 BASED ON THESE HISTORICAL BEST PRACTICES, AND IN A
21 WAY THAT ALIGNS WITH THE NEW AND UPDATED PROGRAM
22 OBJECTIVES THAT HAVE BEEN COMING THROUGH IN OUR
23 STRATEGIC ALLOCATION FRAMEWORK ALIGNED PROGRAMS.

24 SO OUR GOAL IS TO USE THIS FRAMEWORK FOR
25 THE UPCOMING CLIN2 AND PDEV OR PRECLINICAL

BETH C. DRAIN, CA CSR NO. 7152

1 DEVELOPMENT APPLICATION REVIEW SUBCOMMITTEE
2 MEETINGS. AND AS WE RECEIVE FEEDBACK AND AS WE MOVE
3 INTO APPLICATIONS FROM OTHER PROGRAMS, WE'LL MAKE
4 ADJUSTMENTS AS NEEDED.

5 SO THIS FRAMEWORK STARTS WITH DELINEATING
6 THE CIRCUMSTANCES, AND IN THIS CASE THAT MEANS THE
7 GWG OUTCOMES, THAT WOULD PROMPT CIRM TO DEVELOP
8 FUNDING RECOMMENDATIONS. SO FIRST I'M GOING TO GO
9 THROUGH THE THREE OUTCOMES THAT WE CONSIDER HERE.
10 AND THEN IN THE NEXT SLIDE I'LL TALK THROUGH WHAT
11 ARE THE PARAMETERS OR THE DATA ON WHICH THOSE
12 RECOMMENDATIONS MIGHT BE BASED.

13 SO THE FIRST GWG OUTCOME IS AN APPLICATION
14 THAT RECEIVES A MINORITY REPORT. JUST AS A
15 REMINDER, A MINORITY REPORT IS ISSUED WHEN 35
16 PERCENT OR MORE OF THE GRANTS WORKING GROUP MEMBERS
17 SCORE AN APPLICATION WITH A SCORE OF 85 OR ABOVE.
18 SO IN THE FUNDING RANGE. SO IN THAT SITUATION CIRM
19 WILL TAKE A LOOK AT THE REPORT AND AT THE
20 APPLICATION AND MAKE A RECOMMENDATION TO THE
21 ARS ALIGNING WITH EITHER THE MAJORITY OR THE
22 MINORITY POSITION OF THE GRANTS WORKING GROUP.

23 THE SECOND OUTCOME THAT WOULD PROMPT CIRM
24 TO EXAMINE RECOMMENDATIONS ARE APPLICATIONS THAT
25 RECEIVE A MEDIAN GWG SCORE OF 80 OR ABOVE. AND SO

BETH C. DRAIN, CA CSR NO. 7152

1 THIS 80 RANGE REALLY REFLECTS WHERE WE THINK THAT
2 THE GWG HAS INDICATED FEASIBILITY AND POTENTIAL
3 MERIT SO THAT IF THERE'S A BUDGET CIRCUMSTANCE OR A
4 COMPELLING JUSTIFICATION BASED ON THE RECOMMENDATION
5 PARAMETERS, WHICH I'LL SHOW IN A MOMENT, CIRM MAY
6 MAKE A FUNDING RECOMMENDATION THAT COULD DIFFER FROM
7 THE GRANTS WORKING GROUP.

8 AND THEN THE FINAL OUTCOME OR CIRCUMSTANCE
9 WOULD BE TAKING A LOOK AT THE PROGRAM BUDGET. SO IN
10 A CIRCUMSTANCE WHERE THE GWG RECOMMENDS AWARDS THAT
11 EITHER EXCEED THE AVAILABLE FUNDS OR IF CONSIDERING
12 GWG RECOMMENDATIONS ADDITIONAL FUNDS REMAIN IN AN
13 ANNUAL PROGRAM BUDGET, CIRM MAY MAKE RECOMMENDATIONS
14 THAT MATCH UTILIZATION OF THAT BUDGET.

15 ALL RIGHT. AND THEN THE PARAMETERS OR THE
16 DATA THAT CIRM WILL USE IN FORMING A RECOMMENDATION
17 ARE THESE THREE KEY POINTS HERE. THE FIRST IS
18 PORTFOLIO BALANCE. SO WE'LL EXAMINE OUR EXISTING
19 R&D PORTFOLIO. SO IN THIS CASE THIS WOULD BE
20 PRECLINICAL AND CLINICAL AWARDS. AND THEN PRESENT
21 DATA ON WHETHER THE AREA ADDRESSED IN THE
22 APPLICATION UNDER CONSIDERATION MIGHT BE RELATIVELY
23 NOVEL IN OUR PORTFOLIO OR IS IN AN AREA WHERE WE
24 ALREADY HAVE A STRONG REPRESENTATION.

25 IN ADDITION TO LOOKING AT OUR OWN

BETH C. DRAIN, CA CSR NO. 7152

1 PORTFOLIO, WE'LL ALSO CONSIDER THE EXTERNAL
2 LANDSCAPE. SO IN THIS CASE, ESPECIALLY WITH A FOCUS
3 ON TREATMENTS THAT ARE ALREADY AVAILABLE TO PATIENTS
4 OR THOSE THAT ARE IN LATE STAGE TRIALS AND MIGHT
5 SOON BE AVAILABLE, WE WOULD EXAMINE WHETHER THERE
6 ARE ANY RELEVANT EXTERNAL PROGRAMS THAT MAY HAVE AN
7 INFLUENCE ON THE VALUE PROPOSITION OR THE IMPACT OF
8 THE APPLICATION UNDER CONSIDERATION.

9 AND THEN THE THIRD CATEGORY, WHICH WE CALL
10 OTHER FACTORS, IS AN INSTANCE WHERE WE MIGHT PRESENT
11 RELEVANT INFORMATION THAT WE'RE AWARE OF EITHER
12 CONCERNING THE APPLICANT INVESTIGATOR OR INSTITUTION
13 THAT MIGHT BE RELEVANT EITHER TO CIRM'S MISSION, TO
14 PROGRAM OBJECTIVES, OR TO THEIR ABILITY TO CARRY OUT
15 THE ACTIVITIES IN AN APPLICATION AS PROPOSED.

16 AND SO FINALLY, I'LL JUST END WITH AN
17 OVERVIEW OF HOW THIS INFORMATION WOULD BE PRESENTED
18 TO THE ARS FOR ARS FUNDING DECISIONS. I'LL GO
19 THROUGH THE FOUR KEY RESOURCES HERE WITH A FOCUS ON
20 WHAT WILL BE NEW COMING ON THAT DECEMBER 11TH
21 ARS MEETING. AND THOSE NEW RESOURCES ARE
22 HIGHLIGHTED IN BLUE BOXES HERE.

23 SO THE FIRST RESOURCE IS THE PRESENTATION
24 THAT'S GIVEN BY MEMBERS OF OUR REVIEW TEAM WHICH
25 WILL INCLUDE AN OVERVIEW OF THE PROGRAM OR FUNDING

BETH C. DRAIN, CA CSR NO. 7152

1 OPPORTUNITY, A REMINDER OF THE REVIEW PROCESS THAT
2 WAS FOLLOWED, AND THEN INFORMATION ON THE PROGRAM
3 BUDGET, APPLICATIONS THAT RECEIVED MINORITY REPORTS,
4 AND A SUMMARY OF ANY APPLICATIONS WHERE THE GWG
5 RECOMMENDATION AND THE CIRM RECOMMENDATION DIFFER.

6 IN ADDITION TO THAT PRESENTATION, THE
7 ARS WILL ALSO HAVE A COMPLETE SCORE SPREADSHEET.
8 THIS IS TYPICALLY AN EXCEL FILE THAT HAS COMPLETE
9 GWG SCORE INFORMATION FOR ALL OF THE APPLICATIONS
10 UNDER CONSIDERATION AS WELL AS LISTING FOR EACH
11 APPLICATION WHAT IS THE FINAL GWG AND CIRM
12 RECOMMENDATION.

13 ESPECIALLY CRITICAL FOR THESE FUNDING
14 DECISIONS ARE THE GWG SUMMARIES THEMSELVES. THESE
15 ARE COMMENTS THAT ARE PROVIDED BY OUR GRANTS WORKING
16 GROUP REVIEWERS AND PATIENT ADVOCATES. AND OUR
17 REVIEW TEAM CRAFTS THESE INTO A SUMMARY THAT HAS
18 APPLICATION INFORMATION BUT IN A DEIDENTIFIED FORMAT
19 AND WITH THE GWG COMMENTS GROUPED BY REVIEW
20 CRITERION.

21 SOMETHING NEW THAT WILL BE INCLUDED IN
22 THESE SUMMARIES STARTING IN DECEMBER IS A RECAP OF
23 THE KEY STRENGTHS AND WEAKNESSES THAT THE GWG FELT
24 AN APPLICATION HELD. AND THIS IS INTENDED TO HELP
25 FOCUS IN ON RATIONALE FOR A GWG RECOMMENDATION TO

BETH C. DRAIN, CA CSR NO. 7152

1 FUND OR NOT FUND AN APPLICATION.

2 AND THEN THE FINAL RESOURCE WHICH WILL BE
3 NEW STARTING IN DECEMBER IS WHAT WE'RE CALLING A
4 RECOMMENDATION MEMO. AND THIS WILL BE THE DOCUMENT
5 PROVIDED TO THE ARS THAT PRESENTS THE ANALYSIS AND
6 RATIONALE FOR CIRM RECOMMENDATIONS WHEN THOSE
7 RECOMMENDATIONS DIFFER FROM THE GRANTS WORKING
8 GROUP. SO WE CALL IN SOME OF THE PARAMETERS AND THE
9 ANALYSIS THAT WOULD LEAD TO A RECOMMENDATION. THE
10 MEMO WOULD INCLUDE RELEVANT INFORMATION FROM CIRM'S
11 PORTFOLIO AS WELL AS THE EXTERNAL LANDSCAPE THAT
12 PROVIDE A RATIONALE FOR THE CIRM TEAM
13 RECOMMENDATION.

14 SO THAT CONCLUDES THE UPDATE. I'D JUST
15 LIKE TO THANK MY COLLEAGUES WHO HAVE HELPED DEVELOP
16 THESE PRACTICES AND THIS FRAMEWORK. WE LOOK FORWARD
17 TO PRESENTING THIS INFORMATION TO THE ARS IN
18 DECEMBER. AND I'M HAPPY TO TAKE ANY QUESTIONS OR
19 COMMENTS FROM THE SUBCOMMITTEE.

20 CHAIRMAN FISCHER-COLBRIE: ANY QUESTIONS
21 OF LIZ?

22 MR. TOCHER: PAT LEVITT HAS HIS HAND
23 RAISED.

24 DR. NOBLIN: YES. GO AHEAD, PAT.

25 DR. LEVITT: HI, LIZ. SEVERAL THINGS, BUT

BETH C. DRAIN, CA CSR NO. 7152

1 FIRST AS A GENERAL QUESTION. YOU KNOW THE NIH LAST
2 YEAR OR THE YEAR BEFORE MODIFIED A BIT THE REVIEW
3 CRITERIA THAT INCLUDED THREE DOMAINS. ONE IS
4 IMPORTANCE OF RESEARCH WHICH SORT OF REPLACES
5 SIGNIFICANCE. EXPERTISE AND RESOURCES, CAN THE
6 GROUP PULL IT OFF. AND THEN RIGOR AND FEASIBILITY,
7 LIKE IS THE PLAN DETAILED ENOUGH TO KNOW THAT
8 THERE'S RIGOR AND THEY CAN ACTUALLY DO IT. BUT THEN
9 THAT, OF COURSE, SPEAKS TO PRELIMINARY DATA THEY MAY
10 INCLUDE AS WELL AS ANALYTICAL PLANS.

11 SO SINCE I'VE NEVER APPLIED FOR A CIRM
12 GRANT AND DON'T REVIEW CIRM GRANTS, CIRM
13 APPLICATIONS, I'M JUST CURIOUS WHETHER
14 THOSE -- WHETHER THE VARIOUS COMPONENTS THAT ARE IN
15 TERMS OF INSTRUCTIONS THAT ARE PROVIDED ABOUT HOW TO
16 REVIEW A GRANT, WHETHER IT'S BEEN LOOKED AT AND
17 MODIFIED IN SOME WAY, AM I BETTER WITH NIH OR
18 WHETHER YOU FEEL THAT CIRM'S CRITERIA ARE ACTUALLY
19 BETTER THAN THE NIH CRITERIA. THESE CRITERIA WERE
20 CHANGED, I THINK, IN 20 -- IT WAS ANNOUNCED, I
21 THINK, IN 2023 OR SOMETHING LIKE THAT. SO I'M JUST
22 WONDERING THAT. AND THEN I HAVE A FEW FOLLOW-UP
23 QUESTIONS SPECIFICALLY.

24 DR. NOBLIN: THANKS FOR THAT QUESTION. I
25 THINK FOR THE FIRST QUESTION, THAT WOULD PROBABLY BE

BETH C. DRAIN, CA CSR NO. 7152

1 BEST SUITED FOR GIL TO ADDRESS FROM THE PURVIEW OF
2 THE REVIEW TEAM. GIL, DO YOU MIND COMMENTING?

3 DR. SAMBRANO: SURE. NO PROBLEM. THANKS,
4 PAT, FOR THE QUESTION.

5 SO WHAT WE DO IS WE ACTUALLY TAILOR THE
6 REVIEW CRITERIA FOR EACH OF THE OPPORTUNITIES THAT
7 WE HAVE. SO THE REVIEW CRITERIA, FOR EXAMPLE, FOR
8 OUR CLINICAL PROGRAM ARE GOING TO BE QUITE A BIT
9 DIFFERENT FROM THOSE FOR THE DISCOVERY PROGRAM. AT
10 A HIGH LEVEL THEY DO INCLUDE THE BASICS OF OVERALL
11 SIGNIFICANCE AND IMPACT, THE RATIONALE, THEIR PLAN
12 AND DESIGN, FEASIBILITY, AND THEN, OF COURSE, WE
13 INCLUDE POPULATION IMPACT AS ONE OF THE KEY
14 ELEMENTS. SO AT A VERY HIGH LEVEL, WE TRY TO KEEP
15 IT CONSISTENT, BUT WE FINE-TUNE IT FOR EACH OF THE
16 PROGRAMS BECAUSE THEY'RE LOOKING FOR DIFFERENT
17 THINGS.

18 INNOVATION, FOR EXAMPLE, COMES INTO PLAY
19 MORE SPECIFICALLY IN THE EARLY DISCOVERY PROGRAMS
20 WHERE THAT MIGHT BE LESS THE CASE AT THE CLINICAL
21 STAGE, FOR EXAMPLE.

22 DR. LEVITT: OKAY. THANKS. THREE
23 QUESTIONS BASED ON WHAT YOU PRESENTED, LIZ.

24 EXTERNAL PROGRAM INFLUENCE ON, WHICH
25 SPEAKS TO SETTING PRIORITIES, IS THAT FOCUSED ON

BETH C. DRAIN, CA CSR NO. 7152

1 WHAT'S HAPPENING IN CALIFORNIA OR IF THERE'S A
2 CLINICAL TRIAL GOING ON IN NEW YORK, THAT WOULD
3 INFLUENCE THE DECISION ABOUT WHETHER IT'S A HIGH OR
4 LOWER PRIORITY?

5 DR. NOBLIN: YEAH. THANKS FOR THE
6 QUESTION, PAT. SO FOR THIS SPECIFIC PROCESS, WHAT
7 WE WOULD REALLY BE PROVIDING IS SORT OF A COUNT AND
8 AN ANALYSIS, THE POTENTIALLY RELEVANT EXTERNAL
9 PROGRAMS COMPARED TO THE APPLICATION UNDER
10 CONSIDERATION. SO WE ARE CONSIDERING THINGS THAT
11 ARE ON A PATH TO U.S. APPROVAL WITH THE ASSUMPTION
12 THAT THOSE WOULD BE THE THERAPIES THAT WOULD ALSO BE
13 AVAILABLE TO CALIFORNIANS.

14 DR. LEVITT: OKAY. THE UTILIZATION OF THE
15 BUDGET, I UNDERSTAND -- YOU TALK ABOUT TWO
16 COMPONENTS. ONE IS IF THE RECOMMENDED FUNDING IS
17 OVER WHAT THE ALLOCATED BUDGET IS AND THEN ONE IS IF
18 IT'S UNDER.

19 DR. NOBLIN: UH-HUH.

20 DR. LEVITT: I GUESS YOU TALKED ABOUT
21 MATCHING UTILIZATION. I PRESUME THAT WOULD BE IF
22 IT'S UNDER AND THERE WOULD BE AN OPPORTUNITY TO USE
23 RESIDUAL FUNDS THERE. BUT WHAT IS THE -- WHAT
24 IS -- IS THERE ANY CHANGE IN TERMS OF IF IT'S OVER?
25 BECAUSE IF IT'S OVER, THEN THERE'S A DECISION NOT TO

BETH C. DRAIN, CA CSR NO. 7152

1 FUND GRANTS THAT WERE RECOMMENDED FOR FUNDING
2 BECAUSE IT'S OVER THE ALLOCATED ANNUAL BUDGET FOR
3 THAT CATEGORY.

4 DR. NOBLIN: YEAH. SO I THINK THERE HAVE
5 BEEN A COUPLE OF INSTANCES OF THIS IN CIRM'S HISTORY
6 WHERE IF A ROUND IS, I THINK WE USED THE TERM,
7 OVERSUBSCRIBED, CIRM WOULD PROVIDE OUR
8 RECOMMENDATIONS. IF THE ARS WISHED TO STAY WITHIN
9 THE ANNUAL BUDGET, THIS IS HOW WE MIGHT RECOMMEND
10 ACCOMPLISHING THAT. BUT THE ULTIMATE DECISION OF
11 BUDGET UTILIZATION IS WITH THE ARS.

12 DR. LEVITT: OKAY. ALL RIGHT. THEN THE
13 THIRD THING IS SOMETHING THAT RELEVANT INFORMATION
14 OUTSIDE OF APPLICATION LIKE SOMETHING ABOUT, I
15 SUPPOSE, THE APPLICANT OR THE INSTITUTION IN WHICH
16 THE WORK WAS GOING TO DO. HOW IS THAT INFORMATION
17 VALIDATED? LIKE THERE'S INFORMATION AND THERE'S
18 INFORMATION, RIGHT? YOU KNOW WHAT I MEAN. THERE'S
19 INFORMATION AND THEN THERE'S THINGS YOU HEAR ABOUT
20 THAT MAY OR MAY NOT BE VALIDATED AS CONCERNS. SO
21 I'M CURIOUS ABOUT HOW YOU'RE GOING -- HOW THE GROUP
22 IS GOING TO GO ABOUT VALIDATING THAT KIND OF
23 INFORMATION THAT'S OUTSIDE OF THE APPLICATION
24 ITSELF.

25 DR. NOBLIN: YEAH. I THINK IT'S A GREAT

BETH C. DRAIN, CA CSR NO. 7152

1 CALL-OUT, THAT THAT WOULD HAVE TO BE A VERY WELL
2 VETTED PIECE OF INFORMATION. ROSA, GO AHEAD IF YOU
3 WANT TO JUMP IN.

4 DR. CANET-AVILES: YEAH. THANK YOU, PAT.
5 THAT'S A VERY RELEVANT QUESTION. AND THE TEAM
6 THROUGH THE TEAM LEADS, THEY COORDINATE VALIDATING
7 ANY OF THIS INFORMATION DIRECTLY WITH THE APPLICANTS
8 IN BETWEEN THE GRANTS WORKING GROUP RECOMMENDATION
9 AND THE ARS. AND IF IT'S NOT VALIDATED DIRECTLY
10 WITH SOURCES THAT CAN CONFIRM THAT, WE COULD NOT
11 MAKE A RECOMMENDATION.

12 DR. LEVITT: OKAY. THAT'S ALL I HAVE.
13 THANKS.

14 DR. NOBLIN: THANK YOU, ROSA. THANK YOU,
15 PAT.

16 CHAIRMAN FISCHER-COLBRIE: OTHER QUESTIONS
17 OR DISCUSSION POINTS?

18 DR. LEVITT: I ASKED EVERYBODY'S
19 QUESTIONS, I THINK, MARK.

20 CHAIRMAN FISCHER-COLBRIE: WITH THAT, I
21 BELIEVE WE'VE REACHED THE END OF THE AGENDA; IS THAT
22 CORRECT, SCOTT?

23 MR. TOCHER: THAT'S RIGHT. THERE'S JUST
24 ONE MORE REGARDING PUBLIC COMMENT ITEMS THAT ARE NOT
25 ON THE AGENDA.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN FISCHER-COLBRIE: OKAY. GREAT.
2 THANK YOU. SO WITH THAT, IF ANYBODY FROM THE PUBLIC
3 HAVE COMMENTS OR QUESTIONS ON AN OVERALL BASIS?

4 MS. MANDAC: WE HAVE ONE, YOUR CLOCK
5 STARTS NOW.

6 DR. BHATNAGA: I'M PARIJAT BHATNAGA. I
7 HAVE A SPECIFIC QUESTION OR A COMMENT REGARDING THE
8 PROGRAM PDEV. AS I MENTIONED PREVIOUSLY, I STARTED
9 A NONPROFIT, BUT THERE IS A CERTAIN CLAUSE IN THE
10 ELIGIBILITY CRITERIA THAT IS MAKING US INELIGIBLE.
11 MY NONPROFIT IS ELIGIBLE FOR DARPA, FOR NIH AND
12 THAT'S WHERE WE ARE APPLYING FUNDING. AS YOU ALL
13 KNOW, IT'S HARD TO GET FUNDING NOW FROM FEDERAL
14 SOURCES, BUT CALIFORNIA FUNDS ARE THERE. I WAS
15 HOPING THAT I COULD APPLY FOR THE NONPROFIT. BUT
16 ONE ELIGIBILITY CRITERIA IN THE NONPROFIT -- FOR
17 PDEV AND SOME OF THE PROGRAMS IS THAT THEY NEED TO
18 BE AT LEAST ONE W-2 EMPLOYEE. AND WE DON'T HAVE
19 THAT. AND I WANTED TO ASK IF CIRM WOULD RECONSIDER
20 IF IT IS REALLY REQUIRED TO HAVE A W-2 EMPLOYEE.

21 I AM THE CEO, ACTING CEO OF NONPROFIT. WE
22 HAVE THREE BOARD MEMBERS INCLUDING ME, BUT NONE OF
23 US ARE BEING PAID RIGHT NOW BECAUSE WE DON'T HAVE
24 FUNDING. OUR PLAN HAS BEEN THAT WE ARE WRITING
25 PROPOSALS TO NIH AND DARPA HOPEFULLY TO CIRM AS WELL

BETH C. DRAIN, CA CSR NO. 7152

1 IF THE CRITERIA IS RELAXED.

2 IF WE GET THE FUNDING, THEN WE WILL HIRE
3 PEOPLE AND CONDUCT OUR RESEARCH. WE HAVE ALREADY
4 BEEN ALLOTTED SPACE IN INCUBATORS AND ALSO WE HAVE
5 COLLABORATORS IN DIFFERENT UNIVERSITIES WHERE WORK
6 WILL BE CONDUCTED.

7 CHAIRMAN FISCHER-COLBRIE: I THINK WHAT
8 WOULD BE MOST HELPFUL IS TO ACKNOWLEDGE THE COMMENT
9 AND THE QUESTION. I THINK THE MOST EFFICIENT USE OF
10 TIME WOULD BE FOR OUR TEAM TO GET WITH YOU OFFLINE
11 TO FOLLOW UP WITH YOUR PARTICULAR QUESTIONS BECAUSE
12 THAT WAY THERE COULD BE A MORE FULSOME DISCUSSION.
13 AND I'M SURE YOU'RE GOING TO HAVE FOLLOW-UP
14 QUESTIONS. SO IF YOU DON'T MIND, I'D LIKE TO --

15 DR. BHATNAGA: ABSOLUTELY.

16 CHAIRMAN FISCHER-COLBRIE: -- HAVE YOU
17 TALK TO OUR TEAM.

18 DR. BHATNAGA: THANK YOU. YEAH. MY
19 FEELING IS THAT WHEN THIS CRITERIA WAS CREATED, IT
20 MUST -- SUCH A SITUATION MIGHT NOT HAVE BEEN THOUGHT
21 OF. A NONPROFIT IS THERE WITHOUT ANY EMPLOYEES, BUT
22 IT IS A LEGAL ENTITY IN CALIFORNIA, REGISTERED. AND
23 SO IF THIS SUGGESTION COULD BE CONSIDERED AND
24 ELIGIBILITY CRITERIA COULD BE MADE MORE RELAXED,
25 THAT WOULD REALLY BE A BIG HELP TO US.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN FISCHER-COLBRIE: THANK YOU FOR
2 THE COMMENT. AND WE ACKNOWLEDGE IT AND LOOK FORWARD
3 TO HAVING OUR TEAM DISCUSS IT WITH YOU ON A MORE
4 FULSOME BASIS.

5 DR. BHATNAGA: THANK YOU.

6 CHAIRMAN FISCHER-COLBRIE: OTHER COMMENTS,
7 OR QUESTIONS FROM THE PUBLIC?

8 MR. TOCHER: IT DOESN'T APPEAR SO, MARK.

9 CHAIRMAN FISCHER-COLBRIE: OKAY. WITH
10 THAT, WE CAN ADJOURN THE MEETING. THANK YOU,
11 EVERYBODY.

12 (THE MEETING WAS THEN CONCLUDED AT 4:39 P.M.)

13
14
15
16
17
18
19
20
21
22
23
24
25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE VIRTUAL PROCEEDINGS BEFORE THE SCIENCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON NOVEMBER 21, 2025, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152
133 HENNA COURT
SANDPOINT, IDAHO
(208) 920-3543